The Journal of biological chemistry, 2010-11, Vol.285 (45), p.34447-34459
2010
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- The Antioxidant Transcription Factor Nrf2 Negatively Regulates Autophagy and Growth Arrest Induced by the Anticancer Redox Agent Mitoquinone
- Ist Teil von
- The Journal of biological chemistry, 2010-11, Vol.285 (45), p.34447-34459
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2010
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Mitoquinone (MitoQ) is a synthetically modified, redox-active ubiquinone compound that accumulates predominantly in mitochondria. We found that MitoQ is 30-fold more cytotoxic to breast cancer cells than to healthy mammary cells. MitoQ treatment led to irreversible inhibition of clonogenic growth of breast cancer cells through a combination of autophagy and apoptotic cell death mechanisms. Relatively limited cytotoxicity was seen with the parent ubiquinone coenzyme Q10. Inhibition of cancer cell growth by MitoQ was associated with G1/S cell cycle arrest and phosphorylation of the checkpoint kinases Chk1 and Chk2. The possible role of oxidative stress in MitoQ activity was investigated by measuring the products of hydroethidine oxidation. Increases in ethidium and dihydroethidium levels, markers of one-electron oxidation of hydroethidine, were observed at cytotoxic concentrations of MitoQ. Keap1, an oxidative stress sensor protein that regulates the antioxidant transcription factor Nrf2, underwent oxidation, degradation, and dissociation from Nrf2 in MitoQ-treated cells. Nrf2 protein levels, nuclear localization, and transcriptional activity also increased following MitoQ treatment. Knockdown of Nrf2 caused a 2-fold increase in autophagy and an increase in G1 cell cycle arrest in response to MitoQ but had no apparent effect on apoptosis. The Nrf2-regulated enzyme NQO1 is partly responsible for controlling the level of autophagy. Keap1 and Nrf2 act as redox sensors for oxidative perturbations that lead to autophagy. MitoQ and similar compounds should be further evaluated for novel anticancer activity.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0021-9258eISSN: 1083-351XDOI: 10.1074/jbc.M110.133579Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2966059
- Format
- –
- Schlagworte
- Anticancer Drug, Antineoplastic Agents - pharmacology, Apoptosis, Apoptosis - drug effects, Apoptosis - genetics, Autophagy - drug effects, Autophagy - genetics, Cancer Therapy, Cell Biology, Cell Line, Tumor, Checkpoint Kinase 1, Checkpoint Kinase 2, Cytotoxins - pharmacology, Fluorescent Dyes - pharmacology, G1 Phase - drug effects, G1 Phase - genetics, Humans, Intracellular Signaling Peptides and Proteins - genetics, Intracellular Signaling Peptides and Proteins - metabolism, Kelch-Like ECH-Associated Protein 1, Mitochondria, NF-E2-Related Factor 2 - genetics, NF-E2-Related Factor 2 - metabolism, Organophosphorus Compounds - pharmacology, Oxidation-Reduction - drug effects, Oxidative Stress, Oxidative Stress - drug effects, Oxidative Stress - genetics, Phenanthridines - pharmacology, Protein Kinases - genetics, Protein Kinases - metabolism, Protein-Serine-Threonine Kinases - genetics, Protein-Serine-Threonine Kinases - metabolism, S Phase - drug effects, S Phase - genetics, Signal Transduction, Ubiquinone - pharmacology